protein-bound

protein-bound

Linked to polypeptides; not freely circulating in the plasma. Drugs or toxins that are heavily protein-bound have less impact on body receptors and metabolic functions than those that circulate in a free (unbound) state.

protein-bound

said of a chemical bonding of calcium, iodine, iron, copper and other electrolyte ions in the blood to plasma proteins. The bound electrolyte is not immediately available biologically nor is it as vulnerable to sudden loss.

protein-bound-bound iodine (PBI) test
determination of thyroid function by measuring the amount of iodine contained in compounds bound to plasma proteins. It has been largely replaced by radioimmunoassay for the thyroid hormones thyroxine (T4) and tri-iodothyronine (T3).
References in periodicals archive ?
Highly protein-bound drugs are usually kept within the vascular compartment owing to the size of the protein-drug complex.
By feeding sialic acid precursor ManNAc to transgenic rats that over-produce Angiopoietin-like 4 in podocytes, the researchers were able to increase the amount of protein-bound sialic acid, and reduce the amount of protein leakage into the urine by more than 40 percent.
Advocacy of the more efficient dialysis modalities with the high flux (HF) and super-flux (SF) membranes stresses the importance to study the behaviour of non-protein-bound and protein-bound uremic toxins in respect to their removal characteristics with different membranes [5].
DESIGN: Review of three clinical studies beginning in 1975: an uncontrolled study with sodium iodide and protein-bound iodide; a prospective, control, crossover study from iodide to molecular iodine; and a prospective, control, double-blind study with molecular iodine.
Protein-bound lipid is not as damaging to foam as free lipid, although scientists do not know the impact effect of protein binding on lipid oxidation.
Soon-Shiong was honored for his work in developing the first nanoparticle chemotherapy technology, ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), launched in February 2005 for the treatment of metastatic breast cancer.
A paclitaxel protein-bound particles for injectable suspension indicated for the treatment of breast cancer, ABRAXANE was approved by the US Food and Drug Administration in January 2005 and is currently marketed by Abraxis Oncology in North America.
Typically, drugs that are highly protein-bound are not widely distributed--that is, they do not reach many organs but stay in the bloodstream because they are unable to cross biological membranes.
The transaction adds ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) to the company's existing portfolio of leading cancer products and offers another significant scientific platform that may drive future development.
ABRAXANE(TM) (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer.
Similar to protein-bound drugs, it can be expected that the biological activity of the protein-bound solutes is in most cases exerted by the free, non-protein-bound fraction (2-5).

Full browser ?